Effects of di-isononyl phthalate, di-2-ethylhexyl phthalate, and clofibrate in cynomolgus monkeys.
The effects of the peroxisome proliferators di-isononyl phthalate (DINP) and di-2-ethylhexyl phthalate (DEHP) were evaluated in young adult male cynomolgus monkeys after 14 days of treatment, with emphasis on detecting hepatic and other effects seen in rats and mice after treatment with high doses of phthalates. Groups of 4 monkeys received DINP (500 mg/kg/day), DEHP (500 mg/kg/day), or vehicle (0.5% methyl cellulose, 10 ml/kg) by intragastric intubation for 14 consecutive days. Clofibrate (250 mg/kg/day), a hypolipidemic drug used for cholesterol reduction in human patients was used as a reference substance. None of the test substances had any effect on body weight or liver weights. Histopathological examination of tissues from these animals revealed no distinctive treatment-related effects in the liver, kidney, or testes. There were also no changes in any of the hepatic markers for peroxisomal proliferation, including peroxisomal beta-oxidation (PBOX) or replicative DNA synthesis. Additionally, in situ dye transfer studies using fresh liver slices revealed that DINP, DEHP, and clofibrate had no effect on gap junctional intercellular communication (GJIC). None of the test substances produced any toxicologically important changes in urinalysis, hematology, or clinical chemistry; however, clofibrate produced some emesis, small increases in serum triglyceride, decreased calcium, and decreased weights of testes/epididymides and thyroid/parathyroid. The toxicological significance of these small changes is questionable. The absence of observable hepatic effects in monkeys at doses that produce hepatic effects in rodents suggests that DINP, DEHP, and clofibrate would also not elicit in primates other effects such as liver cancer. These data, along with results from in vitro hepatocyte studies, indicate that rodents are not good animal models for predicting the hepatic effects of phthalates in primates, including humans.
Pugh
G
G
Exxon Biomedical Sciences, Inc., East Millstone, New Jersey 08875, USA.
Isenberg
J S
JS
Kamendulis
L M
LM
Ackley
D C
DC
Clare
L J
LJ
Brown
R
R
Lington
A W
AW
Smith
J H
JH
Klaunig
J E
JE
D000284:Administration, Oral; D000818:Animals; D000924:Anticholesteremic Agents / Q000633:toxicity*; D001835:Body Weight / Q000187:drug effects; D002450:Cell Communication / Q000187:drug effects; D002994:Clofibrate / Q000633:toxicity*; D004261:DNA Replication / Q000187:drug effects; D004051:Diethylhexyl Phthalate / Q000378:metabolism / Q000633:toxicity*; D017629:Gap Junctions / Q000187:drug effects; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008252:Macaca fascicularis; D009929:Organ Size / Q000187:drug effects; D010084:Oxidation-Reduction; D020025:Peroxisome Proliferators / Q000009:adverse effects / Q000378:metabolism; D020675:Peroxisomes / Q000187:drug effects* / Q000201:enzymology; D010795:Phthalic Acids / Q000378:metabolism / Q000633:toxicity*
D000924:Anticholesteremic Agents; D020025:Peroxisome Proliferators; D010795:Phthalic Acids; C012125:diisononyl phthalate; D004051:Diethylhexyl Phthalate; D002994:Clofibrate